The proto-oncogene C-Fos transcriptionally regulates VEGF production during peritoneal inflammation

Kidney International

Volumn 84, Issue 6, 2013, Pages 1119-1128

  Catar, Rusan ^a   Witowski, Janusz ^a,b   Wagner, Philine ^a   Annett Schramm, Isa ^a   Kawka, Edyta ^a,b   Philippe, Aurelie ^a   Dragun, Duska ^a   Jörres, Achim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

c Fos; mesothelial cells; peritoneal dialysis; peritonitis; TGF ; VEGF

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN C FOS; SMALL INTERFERING RNA; SR 11302; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DIALYSATE; DNA BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; MESOTHELIUM CELL; NUCLEOTIDE SEQUENCE; ONCOGENE C FOS; PERITONITIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTO ONCOGENE; TRANSCRIPTION REGULATION;

BINDING SITES; CELLS, CULTURED; DIALYSIS SOLUTIONS; EPITHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; PERITONEUM; PERITONITIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888643480     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.217     Document Type: Article

References (52)

1. Mateijsen MA, van der Wal AC, Hendriks PM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525.
2. Honda K, Nitta K, Horita S et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549.
3. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
4. Zweers MM, de Waart DR, Smit W et al. Growth factors VEGF and TGFbeta1 in peritoneal dialysis. J Lab Clin Med 1999; 134: 124-132.
5. Gerber SA, Rybalko VY, Bigelow CE et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006; 169: 1739-1752.
6. Combet S, Miyata T, Moulin P et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000; 11: 717-728.
7. Aroeira LS, Aguilera A, Selgas R et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am J Kidney Dis 2005; 46: 938-948.
8. Mandl-Weber S, Cohen CD, Haslinger B et al. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002; 61: 570-578.
9. Boulanger E, Grossin N, Wautier MP et al. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007; 71: 126-133.
10. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-1265.
11. Selgas R, Bajo A, Jimenez-Heffernan JA et al. Epithelial-to-mesenchymal transition of the mesothelial cell-its role in the response of the peritoneum to dialysis. Nephrol Dial Transplant 2006; 21(Suppl 2): Ii2-ii7.
12. Davies SJ, Mushahar L, Yu Z et al. Determinants of peritoneal membrane function over time. Semin Nephrol 2011; 31: 172-182.
13. Davies SJ, Bryan J, Phillips L et al. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506.
14. Szeto CC, Wong TY, Lai KB et al. The role of vascular endothelial growth factor in peritoneal hyperpermeability during CAPD-related peritonitis. Perit Dial Int 2002; 22: 265-267.
15. Margetts PJ, Kolb M, Yu L et al. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002; 160: 2285-2294.
16. Ni J, Moulin P, Gianello P et al. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 2003; 14: 3205-3216.
17. Margetts PJ, Kolb M, Galt T et al. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol 2001; 12: 2029-2039.
18. Zhang J, Oh KH, Xu H et al. Vascular endothelial growth factor expression in peritoneal mesothelial cells undergoing transdifferentiation. Perit Dial Int 2008; 28: 497-504.
19. Mlambo NC, Hylander B, Brauner A. Increased levels of transforming growth factor beta 1 and basic fibroblast growth factor in patients on CAPD: A study during non-infected steady state and peritonitis. Inflammation 1999; 23: 131-139.
20. Lai KN, Lai KB, Lam CW et al. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35: 644-652.
21. Zemel D, Imholz AL, de Waart DR et al. Appearance of tumor necrosis factor-Alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46: 1422-1430.
22. Moutabarrik A, Nakanishi I, Namiki M et al. Interleukin-1 and its naturally occurring antagonist in peritoneal dialysis patients. Clin Nephrol 1995; 43: 243-248.
23. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001; 25: 158-161.
24. Kenny HA, Krausz T, Yamada SD et al. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer 2007; 121: 1463-1472.
25. Fanjul A, Dawson MI, Hobbs PD et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994; 372: 107-111.
26. Huang C, Ma WY, Dawson MI et al. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 1997; 94: 5826-5830.
27. Brauner A, Hylander B, Wretlind B. Tumor necrosis factor-Alpha, interleukin-1 beta, and interleukin-1 receptor antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 27: 402-408.
28. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene-A concert of activating factors. Cardiovasc Res 2005; 65: 564-573.
29. Xie K, Wei D, Shi Q et al. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 2004; 15: 297-324.
30. Benckert C, Jonas S, Cramer T et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003; 63: 1083-1092.
31. Chua CC, Hamdy RC, Chua BH. Mechanism of transforming growth factorbeta1-induced expression of vascular endothelial growth factor in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 2000; 1497: 69-76.
32. Sanchez-Elsner T, Botella LM, Velasco B et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001; 276: 38527-38535.
33. Szeto CC, Lai KB, Chow KM et al. Differential effects of transforming growth factor-beta on the synthesis of connective tissue growth factor and vascular endothelial growth factor by peritoneal mesothelial cell. Nephron Exp Nephrol 2005; 99: E95-e104.
34. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001; 20: 2438-2452.
35. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41: 2449-2461.
36. Halazonetis TD, Georgopoulos K, Greenberg ME et al. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 1988; 55: 917-924.
37. Herrera R, Agarwal S, Walton K et al. A direct role for c-fos in AP-1-dependent gene transcription. Cell Growth Differ 1990; 1: 483-490.
38. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 2007; 84: 812-822.
39. Rutella S, Fiorino G, Vetrano S et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol 2011; 106: 762-770.
40. Wang B, Trayhurn P. Acute and prolonged effects of TNF-Alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006; 452: 418-427.
41. Ryuto M, Ono M, Izumi H et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996; 271: 28220-28228.
42. McGee DW, Bamberg T, Vitkus SJ et al. A synergistic relationship between TNF-Alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line. Immunology 1995; 86: 6-11.
43. De Benedetti F, Falk LA, Ellingsworth LR et al. Synergy between transforming growth factor-beta and tumor necrosis factor-Alpha in the induction of monocytic differentiation of human leukemic cell lines. Blood 1990; 75: 626-632.
44. Emmanuel C, Foo E, Medbury HJ et al. Synergistic induction of apoptosis in human endothelial cells by tumour necrosis factor-Alpha and transforming growth factor-beta. Cytokine 2002; 18: 237-241.
45. Wang X, Nie J, Jia Z et al. Impaired TGF-beta signalling enhances peritoneal inflammation induced by E. coli in rats. Nephrol Dial Transplant 2010; 25: 399-412.
46. Witowski J, Tayama H, Ksiazek K et al. Human peritoneal fibroblasts are a potent source of neutrophil-targeting cytokines: A key role of IL-1beta stimulation. Lab Invest 2009; 89: 414-424.
47. Yung S, Li FK, Chan TM. Peritoneal mesothelial cell culture and biology. Perit Dial Int 2006; 26: 162-173.
48. Ksíażek K, Jö rres A, Witowski J. Senescence induces a proangiogenic switch in human peritoneal mesothelial cells. Rejuvenation Res 2008; 11: 681-683.
49. Korybalska K, Pyda M, Kawka E et al. Interpretation of elevated serum VEGF concentrations in patients with myocardial infarction. Cytokine 2011; 54: 74-78.
50. Karatas A, Hegner B, de Windt LJ et al. Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. Hypertension 2008; 51: 1177-1183.
51. Finkenzeller G, Sparacio A, Technau A et al. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997; 15: 669-676.
52. Hegner B, Weber M, Dragun D et al. Differential regulation of smooth muscle markers in human bone marrow-derived mesenchymal stem cells. J Hypertens 2005; 23: 1191-1202.